KSHB002 Trial Shows Equivalence to ORENCIA in PK, Safety, and Immunogenicity for RA
The trial aims to establish the pharmacokinetic equivalence, safety, and immunogenicity of KSHB002 compared to ORENCIA in healthy subjects.
Asset / Drug
Drug and asset intelligence for KSHB002 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.